NEW YORK--(BUSINESS WIRE)--July 13, 2006--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today that its lead smallpox drug candidate, SIGA-246, has successfully completed the first planned human clinical safety trial. Preliminary results indicate that SIGA-246 is safe and well-tolerated in human volunteers at all tested oral administered doses. In addition, data from blood level exposure was sufficient to support once a day dosing.
